18129-Lung Cancer-NA-279

Lung Cancer

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG�)Versus Alectinib (ALECENSA�) in Advanced Anaplastic Lymphoma Kinase-Positive Non�Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI�)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number:

  • Address

4370 Medical Arts Drive, Suite 100
Flower Mound, TX 75028
P: (972) 537-4100

Search by practice name, trial titles, indicators and specific disease types.

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.